November 19, 2020

phase 2 trial safety and immunogenicity data from the Oxford COVID-19 vaccine trial including in healthy older adults

The Oxford vaccine have published data from the phase 2 trial of their COVID-19 vaccine candidate, the ChAdOx1 nCoV-19 vaccine.  These results are published in the Lancet and include data on safety and immunogenicity in older adults (age 56 years and over, including people over 70 years old).

Please note – this study does not include any phase 3 data on the Oxford vaccine; that data is not in yet.

Journalists dialled in to this briefing to hear authors of the study discuss these phase 2 results, what the data suggests in terms of likely immune response to the vaccine in older people, what still remains unknown and what the next steps are in the trial.

Speakers included:

Prof Andrew Pollard, chief investigator on the study, and Professor of Paediatric Infection and Immunity, University of Oxford

Prof Sarah Gilbert, lead researcher of the vaccine development programme, and Professor of Vaccinology, University of Oxford

Dr Maheshi Ramasamy, Principal Investigator at the Oxford Vaccine Group, Consultant Physician at the Oxford University Hospitals NHS Foundation Trust, and Honorary Senior Clinical Lecturer, University of Oxford

This Briefing was accompanied by an SMC Roundup of Comments.